Results 271 to 280 of about 833,203 (324)
Designer DNA Architecture‐templated Drug Conjugates (DDA‐DCs) are comprised of a DNA nanomaterial decorated with multiple drug‐loaded DNA aptamers. DDA‐DCs use a combination of multiple aptamer types, each recognizing a different membrane protein to achieve precise targeting of cancer cells.
Abhisek Dwivedy+19 more
wiley +1 more source
Ganoderic acid a potentiates cisplatin's cytotoxicity on gallbladder cancer cells by promoting DNA damage and inhibiting cell stemness. [PDF]
Zhang G+6 more
europepmc +1 more source
H2O2‐Generating Advanced Nanomaterials for Cancer Treatment
H2O2‐generating nanoplatforms can exploit tumor redox imbalance for O2 and toxic reactive oxygen species generation, leading to hypoxia reversal, and apoptosis of cancer cells, respectively. This review highlights the mechanisms of these nanoplatforms, including exogenous H₂O₂ delivery, endogenous amplification, and metal peroxides, which leads to ...
Kiyan Musaie+8 more
wiley +1 more source
Phosphorylated BLM peptide acts as an agonist for DNA damage response. [PDF]
Agrawal R+11 more
europepmc +1 more source
Oct4‐nanoscript, a biomimetic nanoparticle‐based artificial transcription factor, precisely regulates cellular rejuvenation by activating Oct4 target genes, restoring epigenetic marks, and reducing DNA damage. In a progeria model, it effectively rescued aging‐associated pathologies and extended lifespan.
Hongwon Kim+8 more
wiley +1 more source
A toxin-antitoxin system provides phage defense via DNA damage and repair. [PDF]
Pu H+7 more
europepmc +1 more source
Intraoral Drug Delivery: Bridging the Gap Between Academic Research and Industrial Innovations
Intraoral drug delivery offers a promising route for systemic and localized therapies, yet challenges such as enzymatic degradation, limited permeability, and microbial interactions hinder efficacy. This figure highlights innovative strategies—mucoadhesive materials, enzyme inhibitors, and permeation enhancers—to overcome these barriers.
Soheil Haddadzadegan+4 more
wiley +1 more source
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer. [PDF]
Autio KA+9 more
europepmc +1 more source